Dr. Agarwal's Health

Claymore Investments (Mauritius) Pte. Ltd. sold 1.59 crore shares of Dr. Agarwal’s Health Care Ltd. on the open market, crossing the 2% disclosure threshold on 12 August 2026. The sale reduced Claymore’s voting stake from 10.19% to 5.17%, while its PAC, Arvon Investments Pte. Ltd., retained 9.87%, leaving their combined holding at 15.04%. Dr. Agarwal’s Health Care generated ₹2,080 crore of revenue in FY26 and operated 304 facilities across India and overseas. On 12 August, ICICI Prudential Mutual Fund acquired shares in the open market, taking its holding in the company to 5.36%.

Powered by Tijori

Invesco Mutual Fund acquired 69.38 lakh shares of Dr. Agarwal’s Health Care in the open market on 12 August, taking its aggregate holding to 5.2125% from 3.024%. The purchase covered seven schemes and represented 2.1885% of the company’s voting capital; the fund was not part of the promoter group. The transaction followed ICICI Prudential Mutual Fund’s acquisition of a 5.36% holding on the same day, while Claymore Investments and Hyperion Investments disclosed sales of 5.02% and 7.62%, respectively. Dr. Agarwal’s Health Care had revenue of ₹2,080 crore in FY26 and operated 304 facilities at the end of the June quarter.

Powered by Tijori

ICICI Prudential Mutual Fund acquired 16,999,999 shares of Dr. Agarwal's Health Care in the open market on August 12, taking its holding to 5.36% of the paid-up capital and 5.32% on a diluted basis. The fund said the investment was made through its schemes and investment strategies for investment purposes, not to seek control. Dr. Agarwal's Health Care reported consolidated revenue of ₹2,080 crore for FY26 and had 304 facilities at the end of Q1 FY27. It was guiding for 60 new facilities and ₹380-400 crore of capex in FY27.

Powered by Tijori

Aug 4 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:

• DR. AGARWAL'S HEALTH CARE LTD JUNE-QUARTER CONSOL NET PAT 452.3 MILLION RUPEES

• DR. AGARWAL'S HEALTH CARE LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.14 BILLION RUPEES

Source text: ID:nBSEc80jKD

Further company coverage: DRAA.NS

(([email protected];))

By Vibhuti Sharma

MUMBAI, July 13 (Reuters) - India's Maxivision Super Specialty Eye Hospitals, backed by healthcare-focused buyout firm Quadria Capital, has appointed ICICI Securities and IIFL Capital as bankers for a planned 2027 initial public offering, two people familiar with the matter said.

Founded in 1996, Maxivision operates more than 90 eye-care centres across six states. It competes with chains including Dr. Agarwal's Health Care, Centre for Sight and ASG Eye Hospitals in a fast-growing market driven by an ageing population, rising diabetes rates and broader health insurance coverage.

India's eye-care market is projected to grow to $31.2 billion by 2033 from $12.8 billion in 2025, according to Grand View Research.

The Hyderabad-based company is in the early stages of preparing for the IPO, which will include a mix of newly-issued shares and stock sold by existing investors, the sources said.

The size of the IPO has not yet been finalised, they added, requesting anonymity because the talks are private.

Maxivision declined to comment, while ICICI Securities, IIFL Capital and Quadria Capital did not immediately respond to Reuters' queries.

Maxivision's listing plans come amid growing dealmaking and capital markets activity in India's healthcare sector.

Last month, Reuters reported that KKR was in advanced talks to acquire a majority stake in Sweden-based Medicover's MCOVb.ST Indian business for at least $1 billion. Earlier this year, Manipal Health Enterprises filed for an IPO that could raise up to $1.17 billion.

(Reporting by Vibhuti Sharma in Mumbai. Editing by Mark Potter)

(([email protected];))

May 15 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:

• DR. AGARWAL'S HEALTH CARE LTD - GTES TAX NOTICE OF 150.8 MILLION RUPEES PLUS INTEREST AND PENALTY

Source text: ID:nNSE9fp8VP

Further company coverage: DRAA.NS

(([email protected];))

Feb 3 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:

• DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL NET PAT 337.4 MILLION RUPEES

• DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.3 BILLION RUPEES

Source text: [ID:]

Further company coverage: DRAA.NS

(([email protected];;))

** Kotak starts coverage on India's Dr Agarwal's Health Care DRAA.NS with "add" and a fair value of 425 rupees

** Brokerage says high-priced surgical cases, which comprise 62%-65% of the total cases, will boost overall revenue for the eye care services provider over FY28

** Kotak's PT represents a 7.6% upside to DRAA's current price of 394.85 rupees; however, stock down 2% on the day

** Adds, DRAA's strong EBITDA growth trajectory broadly compensates for its currently lower, albeit, improving margins

** Avg rating of three analysts, excluding Kotak, at "buy"; median PT is 502 rupees - data compiled by LSEG

** Stock down 1.7% since trading debut in February

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

March 20 (Reuters) - ** Shares of Dr. Agarwal's Health Care DRAA.NS rise 7.5% to one-month high of 449 rupees

** Motilal Oswal Financial Services initiates coverage on stock with "buy" rating, PT of 510 rupees

** Co to outperform industry growth over the next five years amid latent demand for eye care, coupled with the firm's efforts to treat more patients at existing centers and add new centers, brokerage says

** Sees revenue and EBITDA growing at compounded annual rate of 23% and 21%, respectively, over FY25-FY27

** Higher penetration of insurance to drive an increase in patient volume, it says

** DRAA up nearly 12% after trading debut in early February

(Reporting by Vivek Kumar M)

(([email protected];))

** Shares of recently listed Dr. Agarwal's Health Care DRAA.NS fall 2.8% to 411 rupees, its biggest one-day loss in a month

** Co says India's tax department has demanded payment of 427.4 million rupees ($4.92 million) from the health care co in taxes and penalties

** Co to take steps including filing an appeal against orders

** Stock up 2.2% since its listing on Feb. 4

($1 = 86.8325 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))